The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

Acute myeloid leukemia (AML) is currently treated with aggressive chemotherapy that is not well tolerated in many elderly patients, hence the unmet medical need for effective therapies with less toxicity and better tolerability. Inhibitors of FMS-like tyrosine kinase 3 (FLT3), JAK2 and histone deace...

Descripción completa

Detalles Bibliográficos
Autores principales: Novotny-Diermayr, V, Hart, S, Goh, K C, Cheong, A, Ong, L-C, Hentze, H, Pasha, M K, Jayaraman, R, Ethirajulu, K, Wood, J M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366067/
https://www.ncbi.nlm.nih.gov/pubmed/22829971
http://dx.doi.org/10.1038/bcj.2012.14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366067/
https://www.ncbi.nlm.nih.gov/pubmed/22829971
http://dx.doi.org/10.1038/bcj.2012.14

Ejemplares similares